Sandoz begins Tavist-D cold indication television advertising week of Nov. 11.
This article was originally published in The Tan Sheet
Executive Summary
SANDOZ TAVIST-D COLD INDICATION ADVERTISING KICKS OFF NOV. 11 and continues the Tavist theme of highlighting 12-hour relief. Sandoz received FDA approval of a common cold indication for the antihistamine Tavist-1 and the antihistamine/decongestant Tavist-D on Oct. 31 ("The Tan Sheet" Nov. 4, In Brief). The products, which contain 1.34 mg clemastine fumarate, are the first antihistamines to carry the indication and the only OTCs that contain clemastine fumarate.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning